Several lines of biological evidence have suggested a relationship between the behaviour of melanocytes and cutaneous malignant melanoma (CMM) and the action of female hormones. The present overview, however, indicates that the effect of reproductive, menstrual and hormonal factors, including oral contraceptives, on onset and outcome of CMM must be very weak, if any. The only consistent findings which may suggest a role of female hormones on CMM seem to be: 1) a different distribution by anatomic site in men and women, and 2) a more favorable outcome of CMM in women as compared to men. Neither of them, however, necessarily implies a direct effect of female hormones on CMM.
Get full access to this article
View all access options for this article.
References
1.
AdamS.A., SheavesJ.K., WrightN.H., MosserG., HarrisR.W., VesseyM.P.: A case-control study of the possible association between oral contraceptives and malignant melanoma. Br. J. Cancer, 44: 45–50, 1981.
2.
ArmstrongB.K., EnglishD.R.: The epidemiology of acquired melanocytic naevi and their relationship to malignant melanoma. In: Pigment cell. Elwood J.M. (ed.), 9: 27–47, Karger, Basel, 1988.
3.
ArmstrongB.K., EnglishD.R.: Cutaneous malignant melanoma. In: Cancer Epidemiology and Prevention. Second edition. SchottenfeldD., FraumeniT. (eds.), Chapter 59, in press.
4.
BainC., HennekensC.H., SpeizerF.E., RosnerB., WilletW., BelangerC.: Oral contraceptive use and malignant melanoma. JNCI, 68: 537–539, 1982.
5.
BalchC.M., SoongS.J., ShawH.M.: A comparison of worldwide melanoma data. In: Cutaneous Melanoma. Clinical management and Treatment Resuts Worldwide.BalchC.M., MiltonG.W. (eds.), pp. 507–518, J.B. Lippincott Company, Philadelphia, 1985.
6.
BalchC.M., SoongS.J., ShawH.M., MiltonG.W.: An analysis of prognostic factors in 4000 patients with cutaneous melanoma. In: Cutaneous melanoma. Clinical management and treatment results worldwide.BalchC.M., MiltonG.W. (eds.), pp. 321–352, J.B. Lippincott Company, Philadelphia, 1985.
7.
BeralV., EvansS., ShawH., MiltonG.: Oral contraceptive use and malignant melanoma in Australia. Br. J. Cancer, 50: 681–685, 1984.
8.
BeralV., RamcharanS., FarisR.: Malignant melanoma and oral contraceptive use among women in California. Br. J. Cancer, 36: 804–809, 1977.
9.
BloisM.S., SagebielR.W., AbarbanelR.M., CaldwellT.M., TuttleM.S.: Malignant melanoma of the skin. I. The as sociation of tumor depth and type, and patient sex, age, and site with survival. Cancer, 52: 1330–1341, 1983.
10.
BrintonL.A., MeltonL.J.III, MalkasianG.D., BondA., HooverR.: Cancer risk after evaluation for infertility. Am. J. Epidemiol., 129: 712–722, 1989.
11.
ChaudhuriP.K., WalkerM.J., BrieleH.A., BeattieC.W., Das GuptaT.K.: Incidence of estrogen receptors in benign nevi and human malignant melanoma. JAMA, 244: 791–793, 1980.
12.
CoxE.B., VollmerR.T., SeiglerH.F.: Melanoma in the south-eastern United States: Experience at the Duke Medical Center. In: Cutaneous melanoma. Clinical management and treatment results worldwide.BalchC.M., MiltonG.W. (eds.), pp. 407–418, J.B. Lippincott Company, Philadelphia, 1985.
13.
DevesaS., SilvermanD.T., YoungJ.L., PollackE.S., BrownC.C., HormJ.W., PercyC.L., MyersM.H., McKayF.W., FraumeniJ.F.Jr.: Cancer incidence and mortality trends among whites in the United States, 1947-84. JNCI, 79: 701–770, 1987.
14.
Editorial: Sunburn and melanoma. Lancet, I: 1184, 1987.
15.
EldhJ., BoerydB., SuurkülaM., PetersonL.E., HolmstromH.: Melanoma in Sweden: Experience at the University of Goteborg. In: Cutaneous Melanoma. Clinical management and treatment results worldwide.BalchC.M., MiltonG.W. (eds.), pp. 469–476, J.B. Lippincott Company, Philadelphia, 1985.
16.
EllerbroekW.C.: Oral contraceptives and malignant melanoma. JAMA, 206: 649–650, 1968.
17.
EllisD.L., WheelandR.G., SolomonH.: Estrogen and progesterone receptors in melanocytic lesions: Occurrence in patients with dysplastic nevus syndrome. Arch. Dermatol., 121: 1282–1285, 1985.
ElwoodJ.M., GallagherR.P.: Site distribution of malignant melanoma. Can. Med. Assoc. J., 128: 14C0–1404, 1983.
20.
ElwoodJ.M., GallagherR.P., WorthA.J., WoodW.S., PearsonJ.C.G.: Etiological differences between subtypes of cutaneous malignant melanoma: Western Canada melanoma study. JNCI, 78: 37–44, 1987.
21.
EnglishD.R., HeenanP.J., HolmanC.D.J., ArmstrongB.K., BlackwellJ.B., KelsallG.R.H., MatzL.R., SinghA., Ten SeldamR.E.J.: Melanoma in Western Australia 1975-76 to 1980-81: trends in demographic and pathological characteristics. Int. J. Cancer, 37: 209–215, 1986.
22.
EnglishJ.S.C., SwerdlowA.J., MacKieR.M., O'DohertyC.J., HunterJ.A.A., ClarkJ., HoleD.J.: Relation between phenotype and banal melanocytic naevi. Br. Med. J., 294: 152–154, 1987.
23.
EwertzM., MouridsenH.T.: Second cancer following cancer of the female breast in Denmark, 1943-80. Natl. Cancer Inst. Monogr., 68: 325–330, 1985.
24.
FernoM., BorgA., ErichsenC., IngvarC., JonssonP.E.: Estrogen and progesterone receptors in melanoma metastases with special reference to analytical methods and prognosis. Anticancer Res., 4: 179–182, 1984.
25.
FlowersJ.L., SeiglerH.F., McCarthyK.S.Sr., KonrathJ., McCarthyK.S.Jr.: Absence of estrogen receptor in human melanoma as evaluated by a monoclonal antiestrogen receptor antibody. Arch. Dermatol., 123: 764–765, 1987.
26.
FranceschiS., BidoliE., SerrainoD., TalaminiR.: Melanoma cutaneo e contraccettivi orali: meta-analisi degli studi pubblicati. In: Melanoma cutaneo. Cristofolini M., Piscioli F. (eds.), 1: 77–87, Temi, Trento, 1988.
27.
GallagherR.P., ElwoodJ.M., HillG.B., ColdmanA.J., ThrelfallW.J., SpinelliJ.J.: Reproductive factors, oral contraceptives and risk of malignant melanoma: Western Canada melanoma study. Br. J. Cancer, 52: 901–907, 1985.
HartgeP., TuckerM.A., ShieldsJ.A., AugsburgerJ., HooverR.N., FraumeniJ.F.Jr.: Case-control study of female hormones and eye melanoma. Cancer Res., 49: 4622–4625, 1989.
34.
HarveyE.B., BrintonL.A.: Second cancer following cancer of the breast in Connectitcut, 1935-82. Natn. Cancer Inst. Monogr, 68: 99–112, 1985.
35.
HelmrichS.P., RosenbergL., KaufmanD.W., MillerD.R., SchottenfeldD., StolleyP.D., ShapiroS.: Lack of an elevated risk of malignant melanoma in relation to oral contraceptive use. JNCI, 72: 617–620, 1984.
36.
HerseyP., MorganG., StoneD.E., McCarthyW.H., MiltonG.W.: Previous pregnancy as a protective factor against death from melanoma. Lancet, I: 451–452, 1977.
37.
HollyE.A.: Cutaneous melanoma and oral contraceptives: a review of case-control and cohort studies. In: Recent results in cancer research. Epidemiology of malignant melanoma. Gallagher R.P. (ed.), 102: 108–117, Springer-Verlag, Berlin-Heidelberg, 1986.
38.
HollyE.A.: Melanoma and pregnancy. In: Recent results in cancer research. Epidemiology of malignant melanoma. Gallagher R.P. (ed.), 102: 118–126, Springer-Verlag, Berlin-Heidelberg, 1986.
39.
HollyE.A., WeissN.S., LiffJ.M.: Cutaneous melanoma in relation to exogenous hormones and reproductive factors. JNCI, 70: 827–831, 1983.
40.
HolmanC.D.J., ArmstrongB.K., HeenanP.J.: Cutaneous malignant melanoma in women: Exogenous sex hormones and reproductive factors. Br. J. Cancer, 50: 673–680, 1984.
41.
HolmanC.D.J., ArmstrongB.K., HeenanP.J.: Relationship of cutaneous malignant melanoma to individual sunlight-exposure habits. JNCI, 76: 403–414, 1986.
42.
HoughtonA.N., FlanneryJ., ViolaM.V.: Malignant melanoma of the skin occurring during pregnancy. Cancer, 48: 407–410, 1981.
43.
JelinekJ.E.: Cutaneous side effects of oral contraceptives. Arch. Dermatol., 101: 181–186, 1970.
44.
JensenO.M., BolanderA.M.: Trends in malignant melanoma of the skin. World. Hlth. Stat. Rep., 33: 2–26, 1980.
45.
KarakousisC.P., LopezR.E., BhakooH.S., RosenF., MooreR., CarlsonM.: Estrogen and progesterone receptors and tamoxifen in malignant melanoma. Cancer Treat. Rep., 64: 819–827, 1980.
46.
KayC.R.: Malignant melanoma and oral contraceptives. Br. J. Cancer, 44: 479, 1981.
47.
LedermanJ.S., LewR.A., KohH.K., SoberA.J.: Influence of estrogen administration on tumor characteristics and survival in women with cutaneous melanoma. JNCI, 74: 981–985, 1985.
48.
LeeJ.A.H.: Trend with time of the incidence of malignant melanoma of skin in white population. In: Pigment cell.ElwoodJ.M. (ed.), 9: 1–7, Karger, Basel, 1988.
49.
LeeJ.A.H., StorerB.E.: Excess of malignant melanomas in women in the British Isles. Lancet, II: 1337–1339, 1980.
50.
LeeJ.A., StorerB.E.: Further studies on skin melanoma apparently dependent on female sex hormones. Int. J. Epidemiol., 11: 127–131, 1982.
51.
LernerA.B.: Hormonal control of pigmentation. Ann. Rev. Med., 2: 187, 1960.
52.
LeviF., MaisonneuveP., FilibertiR., La VecchiaC., BoyleP.: Cancer incidence and mortality in Europe. Soz. Praeven-tivmed., 2(Suppl.): S34–S35, 1989.
53.
MacKieR., EnglishJ., AitchisonT., FitzsimonsC., WilsonP.: The number and distribution of benign pigmented moles (melanocytic naevi) in a healthy British population. Br. J. Dermat., 113: 167–174, 1985.
54.
MacKieR., FredenbergerT., AitchisonT.: Personal risk-factor chart for cutaneous melanoma. Lancet, 2: 487–490, 1989.
55.
McCartyK.S.Jr., WortmanJ., StowersS., LubahnD.B., McCartyG.S.Sr., SeiglerH.F.: Sex steroid receptor analysis in human melanoma. Cancer, 46: 1463–1470, 1980.
56.
McLeodG.R., DavisN.C., LittleJ.H., GreenA., ChantD.: Melanoma in Queensland, Australia: Experience of the Queensland melanoma project. In: Cutaneous melanoma. Clinical management and treatment results worldwide.BalchC.M., MiltonG.W. (eds.), pp. 379–387, J.B. Lippincott Company, Philadelphia, 1985.
57.
McPhersonK., VesseyM.P., NeilA., DollR., JonesL., RobertsM.: Early oral contraceptive use and breast cancer: results of another case-control study. Br. J. Cancer, 56: 653–660, 1987.
58.
NichollsE.: Development and elimination of pigmented moles, and the anatomical distribution of primary malignant melanoma. Cancer, 32: 191–195, 1973.
59.
OsterlindA., Hou-JensenK., JensenM.O.: Incidence of cutaneous malignant melanoma in Denmark 1978-1982. Anatomic site distribution, histologic types, and comparison with non-melanoma skin cancer. Br. J. Cancer, 58: 385–391, 1988.
60.
OsterlindA., JensenO.M.: Trends in incidence of malignant melanoma of the skin in Denmark 1943-1982. In: Recent results in cancer research. Epidemiology of malignant melanoma. Gallagher R.P. (ed.), 102: 8–17, Springer-Verlag, Berlin-Heidelberg, 1986.
61.
OsterlindA., JensenO.M.: Letter to the editor. Increasing incidence of trunk melanoma in young Danish women. Br. J. Cancer, 55: 467, 1987.
62.
OsterlindA., OlsenJ.H., LyngeE., EwertzM.: Second cancer following cutaneous melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Denmark, 1943-80. Natl. Cancer Inst. Monogr., 68: 361–388, 1985.
63.
OsterlindA., TuckerM.A., Hou-JensenK., StoneB.J., EngholmG., JensenO.M.The Danish case-control study of cutaneous malignant melanoma. I. Importance of host factors. Int. J. Cancer, 42: 200–206, 1988.
64.
OsterlindA., TuckerM.A., StoneB.J., JensenO.M.: The Danish case-control study of cutaneous malignant melanoma. II. Importance of UV-light exposure. Int. J. Cancer, 42: 319–324, 1988.
65.
OsterlindA., TuckerM.A., StoneB.J., JensenO.M.The Danish case-control study of cutaneous malignant melanoma. III. Hormonal and reproductive factors in women. Int. J. Cancer, 42: 821–824, 1988d.
66.
PackG.T., ScharnagelI.M.: The prognosis for malignant melanoma in the pregnant woman. Cancer, 4: 324–334, 1951.
67.
PrenticeR.L., ThomasD.B.: On the epidemiology of oral contraceptives and disease. In: Advances in cancer research., 49: 285–401, Academic Press Inc., 1987.
68.
RamcharanS., PellegrinF.A., RayR., HsuJ-P.: The Walnut Creek contraceptive drug study, Vol. III, Center for Population Research, NIH, Bethesda1981.
69.
RampenF.H.J., MulderJ.H.: Malignant melanoma: an androgen-dependent tumour?Lancet, I: 562–565, 1980.
ReintgenD.S., PaullD.E., SeiglerH.F., CoxE.B., McCartyK.S.: Sex related survival differences in instances of melanoma. Surg. Gynecol. Obstet., 159: 367–372, 1984.
72.
RiesL.G., PollackE.S., YoungJ.L.Jr.: Cancer patient survival: surveillance, epidemiology, and end results program, 1973-79. JNCI, 70: 693–707, 1983.
73.
RonE., LunenfeldB., MenczerJ., BlumsteinT., KatzL., OelsnerG., SerrD.: Cancer incidence in a cohort of infertile women. Am. J. Epidemiol., 125: 780–790, 1987.
74.
SchwartzB.K., ZashinS.J., SpencerS.K., MillsL.E., SoberA.J.: Pregnancy and hormonal influences on malignant melanoma. J. Dermatol. Surg. Oncol., 13: 276–281, 1987.
75.
ShawH.M., McGovenrV.J., MiltonG.W., FaragoG.A.: Malignant melanoma: Influence of site of lesion and age of patient in the female superiority in survival. Cancer, 46: 2731–2735, 1980.
76.
ShawH.M., MiltonG.W., FaragoG., McCarthyW.H.: Endocrine influences on survival from malignant melanoma. Cancer, 42: 669–677, 1978.
77.
ShiuM.H., SchottenfeldD., MacLeanB., FortnerJ.G.: Adverse effect of prenancy on melanoma: a reappraisal. Cancer, 37: 181–187, 1976.
78.
SnellR.S., BischitzP.G.: The effect of large doses of estrogen and estrogen and progesterone on melanin pigmentation. J. Invest. Dermatol., 35: 73–82, 1960.
79.
StevensR.G., LeeJ.A.H., MoolgavkarS.H.: Correspondence. No association between oral contraceptives and malignant melanomas. N. Engl. J. Med., 302: 966, 1980.
80.
SutherlandC.M., LoutfiA., MatherF.J., CarterC.D., Kre-mentzE.T.: Effect of pregnancy upon malignant melanoma. Surg. Gynecol. Obstet., 157: 443–446, 1983.
81.
SutherlandC.M., WittliffJ.L., FuchsA., MabieW.E.: The effect of pregnancy on hormone levels and receptors in malignant melanoma. J. Surg. Oncol., 22: 191–192, 1983.
82.
ThompsonA.J., CookM.G., GillP.G.: Immunofluorescent detection of hormone receptors in cutaneous melanocytic tumours. Br. J. Cancer, 43: 644–653, 1981.
83.
ThörnM., AdamH-O., RingborgU., BergströmR., Kru-semoU-B.: Long-term survival in malignant melanoma with special reference to age and sex as prognostic factors. JNCI, 79: 969–974, 1987.
84.
TuckerM.A., BoiceJ.D.Jr., HoffmanD.A.: Second cancer following cutaneous melanoma, melanoma and cancers of the brain, thyroid, connective tissue, bone, and eye in Connecticut, 1935-82. Natl. Cancer Inst. Monogr., 68: 161–190, 1985.
85.
VeronesiU., CascinelliN., MorabitoA., BufalinoR., Van Der EschE.P., PredaF., VagliniM., RoviniD., OreficeS.: Prognosis of stage I melanoma of the skin. WHO collaborating centres for evaluation of methods of diagnosis and treatment of melanoma. Int. J. Cancer., 26: 733–739, 1980.
86.
WeissN.S., FlanneryJ.T.: The relationship of marital status to survival from melanoma. Cancer, 42: 296–298, 1978.
87.
WeinstockM.A., ColditzG.A., WillettW.C., StampferM.J., BronsteinB.R., MihmM.C.Jr., SpeizerF.E.: Moles and site-specific risk of nonfamilial cutaneous malignant melanoma in women. JNCI, 81: 948–952, 1989.
88.
WhiteL.P., LindenG., BreslowL., HarzfeldL.: Studies on melanoma: the effect of pregnancy on survival in human melanoma. JAMA, 177: 235–238, 1961.
89.
ZanettiR., FranceschiS., RossoS., BidoliE., ColonnaS.: Cutaneous malignant melanoma in females: the role of hormonal and reproductive factors. Int. J. Epidemiol., 19: 522–526, 1990.
90.
ZavaD.T., GoldhirschA.: Estrogen receptor in malignant melanoma: Fact or artefact? Eur. J. Cancer Clin. Oncol., 19: 1151–1159, 1983.
